Charles River Laboratories (NYSE: CRL) has completed its acquisition of HemaCare Corporation (OTCMKTS: HEMA) for $380 million in cash, or $25.40 per HemaCare share. [Read more…]
Stem Cell News
BioInformant's coverage of stem cell news includes iPS cells, mesenchymal stem cells, hematopoietic stem cells, neural stem cells and more.
As the first and only market research firm to specialize in stem cell news, BioInformant research has been cited by the Wall Street Journal, Xconomy, AABB, and Vogue Magazine.
Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry news.
BMS Pays Evotec $6M as Companies Expand iPSC Collaboration
Adding Cell Types Supports Drug Discovery of Disease-Modifying Therapies for Neurodegenerative Diseases and Triggues U.S. $6 M Payment to EvotecÂ
Hamburg, Germany, January 7, 2020 – Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that the Company received a US$ 6 m payment from Bristol-Myers Squibb Company (NYSE:BMY) following the decision to expand the collaboration to include additional cell lines.
Evotec and Celgene, which is now a Bristol-Myers Squibb company, initiated the collaboration in December 2016 to identify disease-modifying treatments for a broad range of neurodegenerative diseases. Currently approved drugs only offer short-term management of patients’ symptoms and there is a huge unmet medical need for therapies that slow down or reverse disease progression in the field of neurodegenerative diseases.
This collaboration pursues an innovative approach to the discovery and development of novel medicines by leveraging several of Evotec’s unique technology platforms in conjunction with the human iPSC based platform, which is one of the largest and most sophisticated platforms in the industry. The iPSC partnership between Bristol-Myers Squibb and Evotec has already been expanded with additional cell lines several times. [Read more…]
StemBioSys Acquires a Majority Stake in Cartox
SAN ANTONIO, TX and ANN ARBOR, MI, January 8, 2020 – StemBioSys, Inc. (StemBioSys) and CarTox, Inc. (Cartox) are pleased to announce that StemBioSys has acquired a majority stake in Cartox. StemBioSys will acquire all remaining equity of Cartox subject to the achievement of certain milestones. [Read more…]
Adaptimmune Receives RMAT Designation for ADP-A2M4 for Synovial Sarcoma
On December 3, 2019, Adaptimmune Therapeutics (Nasdaq:ADAP) announced it has been granted an Regenerative Medicine Advanced Therapy (RMAT) Designation by the U.S. FDA for ADP-A2M4 in the treatment of Synovial Sarcoma. Previously, the FDA had awarded an Orphan Drug Designation (ODD)Â to ADP-A2M4 for the treatment of soft tissue sarcomas.
This RMAT designation represents the 38th publicly announced RMAT within the United States. [Read more…]
KATAOKA Introduces CPD-017 Cell Processor for High-Speed Biomanufacturing
Unwanted cell removal and cell sorting can be easily performed at high-speed.
TORRANCE, Calif. – Kataoka-SS America, a US subsidiary of Kataoka Corporation Kyoto Japan, has launched its sales of their Cell Processor CPD-017 to the U.S. market. Kataoka`s Cell Processor uses laser technology to scan, identify, and irradiate spontaneously differentiated cells without dissociation or applied stress to the cells.
With the CPD-017, the process time of purifying induced pluripotent stem cell (iPSC) is significantly reduced and the adherent cell colonies can maintain a stress-free healthy condition. [Read more…]
- « Previous Page
- 1
- …
- 107
- 108
- 109
- 110
- 111
- …
- 145
- Next Page »